Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.52 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1316038 | 0.94 | LRRK2 (0.61) | LRRK2SGMS2CYP11B1CYP11B2HDAC1 | |
| SCHEMBL1316825 | 0.92 | LRRK2 (0.52) | LRRK2SGMS2HDAC1MKNK2 | |
| SCHEMBL1316898 | 0.92 | MCL1 (0.47) | LRRK2SGMS2HDAC1SMPD1 | |
| SCHEMBL2574099 | 0.88 | LRRK2 (0.58) | LRRK2SGMS2CYP11B1CYP11B2HDAC1 | |
| SCHEMBL1315304 | 0.88 | SGMS2 (0.45) | LRRK2SGMS2HDAC1MET | |
| SCHEMBL1317655 | 0.87 | GAA (0.46) | LRRK2SGMS2HDAC1MET | |
| SCHEMBL1318557 | 0.86 | LRRK2 (0.52) | LRRK2SGMS2CYP11B1CYP11B2SMPD1 | |
| SCHEMBL1317041 | 0.86 | HDAC1 (0.43) | LRRK2SGMS2HDAC1SMPD1 | |
| SCHEMBL1316188 | 0.86 | LRRK2 (0.52) | LRRK2SGMS2HDAC1 | |
| SCHEMBL1316125 | 0.86 | LRRK2 (0.61) | LRRK2MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102333757-B | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2014-11-26 | — | — | CN | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| CN-102333757-A | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-2385036-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | Toyama Chemical Co., Ltd. (JP) | 2011-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | LRRK2 1813/4885SGMS2 4244/4885CYP11B1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.